loe-exposure
Drug patent expiries ranked by the Medicare Part D spending exposed to them
Should I use this
Quality & Safety
Based on automated analysis of tool definitions and protocol compliance.
Context Cost
This is the approximate number of tokens consumed each time the server's tools are loaded into a model's context. Higher counts reduce the attention available for other tasks.
Install
One-Click Install
Add this to your `claude_desktop_config.json` file:
{
"mcpServers": {
"loe-exposure": {
"url": "https://rxfinder.ai/mcp"
}
}
}Remote endpoints
https://rxfinder.ai/mcpstreamable-httpWhat it can do
Tool inventory
Tools (1)
🟢loss_of_exclusivity_exposure(window, limit)
Rank upcoming FDA Orange Book patent and exclusivity expiries BY the gross Medicare Part D spending exposed to them, with marketed-generic status for each ranked drug resolved from live CMS NADAC price evidence. Answers which expiries matter, not merely which come first. Reports EXPOSURE, never forecast savings. Spending is gross of manufacturer rebates. Orange Book small molecules only, so biologics — among the largest Part D line items — are excluded, and the headline total must not be read as spending that will "go generic".
Input Schema
{
"type": "object",
"properties": {
"window": {
"type": "string",
"description": "Months ahead to include, default 24"
},
"limit": {
"type": "string",
"description": "How many drugs to rank, default 25"
}
},
"required": []
}Community
Evidence